The ethics of CYP2D6 testing for patients considering tamoxifen
If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2007-04-13
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
BioMed Central
Abstract
The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.
Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Hartman, AR., Helft, P. The ethics of CYP2D6 testing for patients considering tamoxifen. Breast Cancer Res 9, 103 (2007). https://doi.org/10.1186/bcr1663
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Commentary
Source
Publisher
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version